The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).
Jenny J. Ko(Abbotsford Veterinary Clinic), Toni K. Choueiri(Harvard University), Sumanta K. Pal(City of Hope), Aristotelis Bamias(National and Kapodistrian University of Athens), Lauren C. Harshman(Dana-Farber Cancer Institute), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Jae‐Lyun Lee(Ulsan College), Wanling Xie(Dana-Farber Cancer Institute), Jennifer J. Knox(National Cancer Center), Nils Kroeger(Universitätsmedizin Greifswald), Ulka N. Vaishampayan(University of Michigan), D. Scott Ernst, Lori Wood(Dalhousie University), Martin Smoragiewicz(University of Cambridge), Takeshi Yuasa(Japanese Foundation For Cancer Research), Neeraj Agarwal(University of Utah), Sun Young Rha(Yonsei University), Daniel Yick Chin Heng(University of Calgary), Brian I. Rini(Vanderbilt University Medical Center)
Cited by 10
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k